1. Home
  2. CUB vs TSHA Comparison

CUB vs TSHA Comparison

Compare CUB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUB
  • TSHA
  • Stock Information
  • Founded
  • CUB 2024
  • TSHA 2019
  • Country
  • CUB United States
  • TSHA United States
  • Employees
  • CUB N/A
  • TSHA N/A
  • Industry
  • CUB
  • TSHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUB
  • TSHA Health Care
  • Exchange
  • CUB NYSE
  • TSHA Nasdaq
  • Market Cap
  • CUB 310.7M
  • TSHA 334.1M
  • IPO Year
  • CUB 2024
  • TSHA 2020
  • Fundamental
  • Price
  • CUB $10.23
  • TSHA $1.72
  • Analyst Decision
  • CUB
  • TSHA Strong Buy
  • Analyst Count
  • CUB 0
  • TSHA 8
  • Target Price
  • CUB N/A
  • TSHA $6.63
  • AVG Volume (30 Days)
  • CUB 36.7K
  • TSHA 1.6M
  • Earning Date
  • CUB 01-01-0001
  • TSHA 02-26-2025
  • Dividend Yield
  • CUB N/A
  • TSHA N/A
  • EPS Growth
  • CUB N/A
  • TSHA N/A
  • EPS
  • CUB N/A
  • TSHA N/A
  • Revenue
  • CUB N/A
  • TSHA $8,333,000.00
  • Revenue This Year
  • CUB N/A
  • TSHA N/A
  • Revenue Next Year
  • CUB N/A
  • TSHA N/A
  • P/E Ratio
  • CUB N/A
  • TSHA N/A
  • Revenue Growth
  • CUB N/A
  • TSHA N/A
  • 52 Week Low
  • CUB $9.96
  • TSHA $1.19
  • 52 Week High
  • CUB $10.55
  • TSHA $4.32
  • Technical
  • Relative Strength Index (RSI)
  • CUB N/A
  • TSHA 54.32
  • Support Level
  • CUB N/A
  • TSHA $1.66
  • Resistance Level
  • CUB N/A
  • TSHA $1.79
  • Average True Range (ATR)
  • CUB 0.00
  • TSHA 0.11
  • MACD
  • CUB 0.00
  • TSHA 0.01
  • Stochastic Oscillator
  • CUB 0.00
  • TSHA 47.62

About CUB LIONHEART HOLDINGS

Lionheart Holdings is a blank check company.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: